Causal inference for definitive clinical end points in a randomized clinical trial with intervening nonrandomized treatments

Journal of Clinical Oncology

Volumn 28, Issue 24, 2010, Pages 3800-3802

  Korn, Edward L ^a   Freidlin, Boris ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOLOGOUS STEM CELL TRANSPLANTATION; CAUSAL ATTRIBUTION; CHEMOTHERAPY; EDITORIAL; HUMAN; METHODOLOGY; NEUROBLASTOMA; OVERALL SURVIVAL; PARAMETER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; AUTOTRANSPLANTATION; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; KAPLAN MEIER METHOD; NOTE; PROGNOSIS; RISK FACTOR; STATISTICAL MODEL; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; CAUSALITY; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIERS ESTIMATE; MODELS, STATISTICAL; NEUROBLASTOMA; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK FACTORS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 77956257982     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.0442     Document Type: Editorial

References (11)

1. Korn EL: Causal inference in the medical area. Stat Sci 21:310-312, 2006
2. London WB, Frantz CN, Campbell LA, et al: Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: A Children's Oncology Group study. J Clin Oncol 28:3808-3815, 2010
3. Korn EL, Baumrind S: Clinician preferences and the estimation of causal treatment differences. Stat Sci 13:209-235, 1998 (Pubitemid 128466409)
4. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456, 2008
5. Escudier B, Eisen T, Stadler WM, et al: Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. J Clin Oncol 27:3312-3318, 2009
6. Sobrero AF, Maurel J, Fehrenbacher L, et al: EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311-2319, 2008
7. Kaufman B, Mackey JR, Clemens MR, et al: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM Study. J Clin Oncol 27:5529-5537, 2009
8. Robbins JM, Tsiatis AA: Correcting for non-compliance in randomized trials using rank preserving structural failure time models. Commun Stat-Theor M 20:2609-2631, 1991
9. Branson M, Whitehead J: Estimating a treatment effect in survival studies in which patients switch treatment. Stat Med 21:2449-2463, 2002 (Pubitemid 34960010)
10. Yamaguchi T, Ohashi Y: Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part II: An application in a clinical trial or unresectable non-small-cell lung cancer. Stat Med 23:2005-2022, 2004
11. National Institute for Health and Clinical Excellence: Sunitinib for the treatment of gastrointestinal stromal tumours. National Institute for Health and Clinical Excellence technology appraisal document 179. http://guidance.nice. org.uk/TA179